Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD

Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Moussab Damlaj, Mohammad Snnallah, Razan Bashir, Inaam Shehab Eddine, Bader Alahmari, Hind Salama, Ahmed Alaskar, Ayman Alhejazi, Mohsen Alzahrani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research